(From left) Paratus Sciences head of therapeutics discovery Lewis Hong, ClavystBio CEO Khoo Shih, DPM Heng Swee Keat and ClavystBio chairman Fidah Alsagoff. — The Straits Times
SINGAPORE: A Temasek-backed biotech investor has unveiled its new research and collaboration centre in Singapore.
ClavystBio, which invests in biotech startups, accommodates four of its 11 portfolio companies at the 13,000-sq-ft facility called Node 1 at Singapore Science Park in Queenstown.
The firm provides these startups, which are based either here or in the United States, with communal resources such as laboratories and offices.
ClavystBio chairman and Temasek head of life sciences Fidah Alsagoff said the company was set up in 2022 to help speed up the commercialisation of local life science breakthroughs to the rest of the world.
“The opening of ClavystBio’s Node 1 strengthens this mission by fostering partnerships across the industry.
“With the support of Temasek’s network and ecosystem, we hope to advance Singapore as a global life sciences translational hub,” he said.
One of ClavystBio’s portfolio companies, Paratus Sciences, which recently raised US$100mil in a Series A funding round, said the spaces at Node 1 will enable it to focus on research and development.
Lewis Hong, the head of therapeutics discovery at Paratus Sciences, said: “We not only gain access to a network of brilliant minds, but also contribute to a collective mission of translating scientific breakthroughs into human health impact.”
Node 1 also houses Polaris Partners, one of ClavystBio’s three venture capital partners, alongside Lightstone Ventures and Accelerator Life Science Partners.
ClavystBio partnered Lightstone Ventures, Polaris Partners and Leaps by Bayer – the corporate venture capital arm of German pharmaceutical giant Bayer – to establish 65Lab, a start-up incubator dedicated to new drug discovery. — The Straits Times/ANN
